Hepatitis associated aplastic anemia during SARS-CoV-2 pandemic

The hepatitis-associated aplastic anemia is one of the acquired bone marrow failure syndromes. It is a stereotyped form of presentation of aplastic anemia and accounts for 2 - 5 % of the cases in the West. Its treatment, which does not differ from that of aplastic anemia, consists of immunosuppressi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Santarelli, Ignacio Martín, Manzella, Pedro Oscar, Gasco González, Francisco, Ingold, Julián José, Olivieri, Melissa Alejandra, Cloobs Venezia, Maximiliano Ariel, Fernández, Sofía Isabel, Melero, Marcelo José
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2022
Materias:
anemia, aplastic
hepatitis
coronavirus infections
anemia aplásica
infecciones por coronavirus
anemia aplástica
hepatite
infecções por coronavirus
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/35138
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba
Descripción
Sumario:The hepatitis-associated aplastic anemia is one of the acquired bone marrow failure syndromes. It is a stereotyped form of presentation of aplastic anemia and accounts for 2 - 5 % of the cases in the West. Its treatment, which does not differ from that of aplastic anemia, consists of immunosuppression when bone marrow transplant is not possible. Nonetheless, during the SARS-CoV-2 pandemic, recommendations restricting the use of antithymocyte globulin to those cases with the highest risk of death have been issued, since the prognosis of CoViD-19 tends to be worse if administered. We present an otherwise-healthy 18-year-old male who was diagnosed with a hepatitis-associated aplastic anemia and received a personalized treatment following these recommendations.

Ejemplares similares